All In Biotech

NDA 021093 · Ani Pharms

Atacand Hct

Candesartan Cilexetil, Hydrochlorothiazide · Oral · Thiazide Diuretic

Last checked: Nov 20, 2026Latest source record: Aug 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Sep 5, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

176

52 Phase 3, 9 recruiting

FAERS reports

2,609

2,165 serious, 170 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue candesartan cilexetil and hydrochlorothiazide tablets as soon as possible. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity

What it is approved for

From the label in effect Dec 22, 2025.

INDICATIONS AND USAGE Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased...

Mechanism: Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ATACAND HCT · CANDESARTAN CILEXETIL 32MG; HYDROCHLOROTHIAZIDE 12.5MG · TABLET, ORAL · Prescription · TE AB
  • ATACAND HCT · CANDESARTAN CILEXETIL 32MG; HYDROCHLOROTHIAZIDE 25MG · TABLET, ORAL · Prescription · TE AB
  • ATACAND HCT · CANDESARTAN CILEXETIL 16MG; HYDROCHLOROTHIAZIDE 12.5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Candesartan Cilexetil" as an intervention, any sponsor and status, largest first.

All 176 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective311
  • blood pressure increased239
  • hypertension224
  • dizziness196
  • dyspnoea132
  • fatigue126
  • nausea124
  • headache120
  • drug dose omission107
  • fall106
  • malaise103
  • off label use101

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200420
200545
200665
200789
2008103
2009139
2010152
2011376
2012525
2013170
2014127
2015126
201667
201754
201874
201995
202083
202181
202253
202334
202462
202541
202628

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Atacand HCT (Candesartan/Hydrochlorothiazid)

2024 spending

$512K

Beneficiaries

193

852 claims

Per beneficiary

$2,655

$9.32 per unit

View as table
YearSpending
2020$973,732
2021$829,718
2022$718,916
2023$609,185
2024$512,365

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 182 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.